HAVCR2 and melanoma: Clinical outcome of anti-CTLA-4 treatment in melanoma patients correlates with low expression of TIM-3 on circulating T and NK cells prior to and during therapy, and correlates with an increased frequency of mature circulating CD3−CD56dimCD16+ NK cells during treatment (51).